Jiangsu Key Laboratory of Oral Disease, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China.
Mol Med Rep. 2019 Nov;20(5):4340-4348. doi: 10.3892/mmr.2019.10665. Epub 2019 Sep 10.
Head and neck squamous cell carcinoma (HNSCC) is highly prevalent worldwide, and the outcome of HNSCC is still difficult to predict due to the lack of appropriate prognostic markers. In the present study, a prognostic model based on a miRNA panel was established to better predict the survival of HNSCC patients. miRNA expression data and clinical information regarding HNSCC patients were acquired from The Cancer Genome Atlas (TCGA) database. Accompanying clinical data was obtained from the University of California, Santa Cruz (UCSC) Xena browser. Using this data, 140 differentially expressed miRNAs (DEMs) were identified between HNSCC tissue samples (n=525) and adjacent normal tissue samples (n=44). The present prognostic model included seven miRNAs (i.e. hsa‑miR‑499a, hsa‑miR‑548k, hsa‑miR‑3619, hsa‑miR‑99a, hsa‑miR‑137, hsa‑miR‑3170, and hsa‑miR‑654), which were identified using least absolute shrinkage and selection operator (LASSO) and Cox regression analyses. The independence of the predictive power of this model was validated by further analyses using clinical information. The outstanding performance of the seven‑miRNA prognostic model was confirmed by time‑dependent receiver operating characteristic curve (ROC) analysis. These results indicated that combining the miRNA panel with pathological characteristics may provide a more accurate prognosis for HNSCC. Functional identification of the target genes of the focal miRNAs using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were also performed. The present study demonstrated that the novel miRNA panel reported here may be useful in making different prognoses and may improve the clinical management of patients with HNSCC.
头颈部鳞状细胞癌(HNSCC)在全球范围内高发,由于缺乏合适的预后标志物,HNSCC 的预后仍然难以预测。在本研究中,建立了基于 miRNA 谱的预后模型,以更好地预测 HNSCC 患者的生存情况。从癌症基因组图谱(TCGA)数据库中获取了 miRNA 表达数据和 HNSCC 患者的临床信息。从加利福尼亚大学圣克鲁兹分校(UCSC)Xena 浏览器中获得了伴随的临床数据。使用这些数据,在 HNSCC 组织样本(n=525)和相邻正常组织样本(n=44)之间鉴定出 140 个差异表达 miRNA(DEM)。本预后模型包括七个 miRNA(即 hsa-miR-499a、hsa-miR-548k、hsa-miR-3619、hsa-miR-99a、hsa-miR-137、hsa-miR-3170 和 hsa-miR-654),这些 miRNA 是使用最小绝对收缩和选择算子(LASSO)和 Cox 回归分析鉴定的。通过使用临床信息进一步分析验证了该模型预测能力的独立性。通过时间依赖性接收器工作特征曲线(ROC)分析证实了该七个 miRNA 预后模型的出色性能。这些结果表明,将 miRNA 谱与病理特征相结合可能为 HNSCC 提供更准确的预后。使用基因本体论(GO)和京都基因与基因组百科全书(KEGG)通路富集分析对焦点 miRNA 的靶基因进行功能鉴定。本研究表明,本研究报道的新型 miRNA 谱可能有助于做出不同的预后,并可能改善 HNSCC 患者的临床管理。